Halozyme Therapeutics Inc
NASDAQ:HALO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
33.68
64.42
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Halozyme Therapeutics Inc
Revenue
Halozyme Therapeutics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
Revenue
$947.4m
|
CAGR 3-Years
27%
|
CAGR 5-Years
36%
|
CAGR 10-Years
32%
|
||
Abbvie Inc
NYSE:ABBV
|
Revenue
$55.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
||
Amgen Inc
NASDAQ:AMGN
|
Revenue
$32.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
Halozyme Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
Halozyme Therapeutics Inc
Total Revenue:
829.3m
USD
|
United States:
587.2m
USD
|
Switzerland:
149m
USD
|
Belgium:
58.4m
USD
|
All Other Foreign:
19.6m
USD
|
Japan:
15.1m
USD
|
Breakdown by Segments
Halozyme Therapeutics Inc
Total Revenue:
829.3m
USD
|
Royalties:
447.9m
USD
|
Product Sales, Net:
300.9m
USD
|
Revenues Under Collaborative Agreements:
80.5m
USD
|
Sale Of Device Partnered Products:
54.6m
USD
|
Halozyme Therapeutics Inc
Glance View
Halozyme Therapeutics Inc., a California-based biopharmaceutical company, weaves innovation with practicality in the realm of drug delivery. The narrative of Halozyme is centered around its proprietary enzyme technology, known as ENHANZE®. This platform is a transformative approach that leverages a recombinant human hyaluronidase enzyme, named rHuPH20. This enzyme temporarily degrades hyaluronan, a key component in the extracellular matrix, thereby allowing for quicker dispersal and absorption of subcutaneous drugs. By facilitating the transition of therapies from intravenous to subcutaneous administration, Halozyme not only enhances the patient experience with less clinic time and reduced infusion-related costs but also provides pharmaceutical partners with the opportunity to extend the lifecycle of their drugs. The company’s revenue generation resembles a carefully orchestrated symphony, harmonizing collaboration and licensing agreements with prominent pharmaceutical giants such as Roche and Bristol-Myers Squibb. Halozyme earns through a blend of upfront licensing fees, milestone payments, and royalties on product sales that incorporate the ENHANZE® technology. These alliances empower its partners to broaden the utility of their existing drug formulations, while Halozyme benefits from a steady cash inflow that supports its ongoing research and development activities. In essence, Halozyme’s business model thrives on creating value by enhancing drug delivery mechanisms, ensuring that its innovations are profitable not only for the partners it collaborates with but also for patients worldwide who benefit from its advancements.
See Also
What is Halozyme Therapeutics Inc's Revenue?
Revenue
947.4m
USD
Based on the financial report for Sep 30, 2024, Halozyme Therapeutics Inc's Revenue amounts to 947.4m USD.
What is Halozyme Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
32%
Over the last year, the Revenue growth was 21%. The average annual Revenue growth rates for Halozyme Therapeutics Inc have been 27% over the past three years , 36% over the past five years , and 32% over the past ten years .